Molecular targets for therapeutic interventions in human papillomavirus-related cancers (review)

Oncology Reports

Volumn 24, Issue 6, 2010, Pages 1419-1426

  Ramalho, Alan Saito ^a   Lopes, Anselmo Dantas ^a   Talans, Aleylove ^a   Sakiyama, Bruno Yoshihiro Parlato ^a   Pereira, Guilherme Luiz Stelko ^b   Hoff, Paulo Marcelo ^a,b   De Castro Jr , Gilberto ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto do Cancer do Estado de Sao Paulo   (Brazil)

Author keywords

Cervical cancer; Human papillomaviruses; Mammalian target of rapamycin; Molecular targeted therapies; Tyrosine kinase receptors

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ADAPHOSTIN; AMG 102; BEVACIZUMAB; BGT 226; BIIB 022; CEDIRANIB; CETUXIMAB; CISPLATIN; CP 721871; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; LONAFAMIB; NIMOTUZUMAB; OSI 906; PANITUMUMAB; PERIFOSINE; PHOSPHOTRANSFERASE; PLX 4032; RIDAFOROLIMUS; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN RECEPTOR; TEMSIROLIMUS; TOPOTECAN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 228; XL 518; XL 880;

ANGIOGENESIS; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAZIL; CANCER INCIDENCE; CARCINOGENESIS; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; EPITHELIUM CELL; HUMAN; INFECTION; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; URINARY TRACT FISTULA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VAGINA BLEEDING; WART VIRUS;

ALPHAPAPILLOMAVIRUS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, VIRAL; FEMALE; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649435189     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001001     Document Type: Article

References (85)

1. Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999.
2. Parkin DM and Bray F: Chapter 2: the burden of HPV-related cancers. Vaccine 24: 11-25, 2006.
3. Cutts FT, Franceschi S, Goldie S, et al: Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 85: 719-726, 2007. (Pubitemid 47416724)
4. International Agency for Research on Cancer-IARC monograph on the evaluation of carcinogenic risks to humans. Human papillomaviruses. IARC monograph: 90, 2005.
5. Frisch M and Goodman MT: Human papillomavirus-associated carcinomas in Hawaii and the mainland U.S. Cancer 88: 1464-1469, 2000. (Pubitemid 30155186)
6. Syrjänen S: HPV infections and tonsillar carcinoma. J Clin Pathol 57: 449-455, 2004.
7. Brasil. Ministério da Saúde. Instituto Nacional de Câncer-INCA. Estimativas de incidência e mortalidade por câncer. Rio de Janeiro, 2008. Available at http://www.inca.gov.br/ estimativa/ 2008/versaofinal.pdf. Accessed in 16 Jul 2009.
8. Muñoz N, Bosch FX, de Sanjosé S, et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003. (Pubitemid 36159887)
9. zur Hausen H: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92: 690-698, 2000.
10. Clifford GM, Gallus S, Herrero R, et al: Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991-998, 2005.
11. de Sanjose S, Almirall R, Lloveras B, et al: Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 30: 788-793, 2003.
12. Franco EL, Villa LL, Sobrinho JP, et al: Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180: 1415-1423, 1999.
13. Trottier H and Franco EL: The epidemiology of genital human papillomavirus infection. Vaccine 24: 1-15, 2006.
14. Ekwueme DU, Chesson HW, Zhang KB and Balamurugan A: Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003. Cancer 113: 2936-2945, 2008.
15. Myers ER, McCrory DC, Nanda K, Bastian L and Matchar DB: Mathematical model for the natural history of human papillo-mavirus infection and cervical carcinogenesis. Am J Epidemiol 151: 1158-1171, 2000.
16. Howley PM and Lowy DR: Papilloma viruses. In: Fields Virology. Knipe DM, Howley PM and Griffin DE (eds.). chapter 62. Lippincott, Williams & Wilkins, Philadelphia, 5th edition, 2007.
17. Munger K, Baldwin A, Edwards KM, et al: Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78: 11451-11460, 2004.
18. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
19. zur Hausen H: Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384: 260-265, 2009.
20. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 5770, 2000.
21. O'Brien PM and Saveria-Campo M: Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res 88: 103-117, 2002.
22. Toussaint-Smith E, Donner DB and Roman A: Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 23: 2988-2995, 2004.
23. Li Y, Nichols MA, Shay JW and Xiong Y: Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54: 6078-6082, 1994.
24. Kim SH, Koo BS, Kang S, et al: HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer 120: 1418-1425, 2007.
25. Kersemaekers AM, Fleuren GJ, Kenter GG, et al: Oncogene alterations in carcinoma of the uterine cervix: Overexpression of the epidermal growth factor receptor as associated with poor prognosis. Clin Cancer Res 5: 577-587, 1999.
26. Kristensen GB, Holm R, Abeler VM and Tropé CG: Evaluation of the prognostic significance of cathepsin D epidermal growth factor receptor and C-ERBB-2 in early cervical squamous carcinoma. Cancer 78: 433-440, 1996.
27. Kurtz JE, Hardy-Bessard AC, Deslandres M, et al: Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II trial. Gynecol Oncol 113: 16-20, 2009.
28. Ferreira CG, Erlich F, Carmo CC, et al: Erlotinib combined with cisplatin and radiotherapy for patients with locally advanced squamous cell cervical cancer: A phase II trial. J Clin Oncol 26: 5511, 2008.
29. Schilder RJ, Sill MW, Lee YC and Mannel R: A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 19: 929-933, 2009.
30. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925, 2003.
31. Gentile A, Trusolino L and Comoglio PM: The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 27: 85-94, 2008.
32. Walker F, Kermorgant S, Daraï E, Madelenat P, Cremieux AC, Hénin D, et al: Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus. Clin Cancer Res 9: 273-284, 2003.
33. Sachdev D and Yee D: Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6: 1-12, 2007.
34. Pollak M: Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res 174: 49-53, 2007.
35. Sciacca L, Costantino A, Pandini G, et al: Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/ paracrine mechanism. Oncogene 18: 2471-2479, 1999.
36. Serrano ML, Sánchez-Gómez M, Bravo MM, Yakar S and LeRoith D: Differential expression of IGF-I and insulin receptor isoforms in HPV positive and negative human cervical cancer cell lines. Horm Metab Res 40: 661-667, 2008.
37. Sabatini DM: mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734, 2006.
38. Granville CA, Memmott RM, Gills JJ and Dennis PA: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 12: 679-689, 2006.
39. Fausch SC, Fahey LM, Da Silva DM and Kast WM: Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol 174: 7172-7178, 2005.
40. Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, et al: Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog 47: 446-457, 2008.
41. Faried LS, Faried A, Kanuma T, et al: Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer 42: 934-947, 2006.
42. Brown RE, Zhang PL, Lun M, et al: Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma. Ann Clin Lab Sci 36: 273-282, 2006.
43. Bertelsen BI, Steine SJ, Sandvei R, Molven A and Laerum OD: Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer 118: 1877-1883, 2006.
44. Charette ST and McCance DJ: The E7 protein from human papillomavirus type 16 enhances keratinocyte migration in an Akt-dependent manner. Oncogene 15: 7386-7390, 2007.
45. Menges CW, Baglia LA, Lapoint R and McCance DJ: Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. Cancer Res 66: 5555-5559, 2006.
46. Contreras-Paredes A, De la Cruz-Hernández E, Martínez- Ramírez I, Dueñas-González A and Lizano M: E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway. Virology 383: 78-85, 2009.
47. Plas DR and Thompson CB: Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24: 7435-7442, 2005.
48. Sebolt-Leopold JS and Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947, 2004.
49. Kiaris H and Spandidos D: Mutations of ras genes in human tumors. Int J Oncol 7: 413-421, 1995.
50. Zachos G and Spandidos DA: Expression of ras proto-oncogenes: regulation and implications in the development of human tumors. Crit Rev Oncol Hematol 26: 65-75, 1997.
51. Rajalingam K, Schreck R, Rapp UR and Albert S: Ras oncogenes and their downstream targets. Biochim Biophys Acta 1773: 1177-1195, 2007.
52. DiPaolo JA, Woodworth CD, Popescu NC, Notario V and Doniger J: Induction of human cervical squamous cell carcinoma by sequential transfection with humanpapillomavirus 16 DNA and viral Harvey ras. Oncogene 4: 395-399, 1989.
53. Durst M, Gallahan D, Jay G and Rhim JS: Glucocorticoid-enhanced neoplastic transformation of human keratinocytes by human papillomavirus type 16 and an activated ras oncogene. Virology 173: 767-771, 1989. (Pubitemid 20014510)
54. Alonio LV, Picconi MA, Dalbert D, et al: Ha-ras oncogene mutation associated to progression of papilomavirus induced lesions of uterine cervix. J Clin Virol 27: 263-269, 2003.
55. Córdova-Alarcón E, Centeno F, Reyes-Esparza J, García- Carrancá A and Garrido E: Effects of HRAS oncogene on cell cycle progression in a cervical cancer-derived cell line. Arch Med Res 36: 311-316, 2005.
56. Landro ME, Dalbert D, Picconi MA, et al: Human papillomavirus and mutated H-ras oncogene in cervical carcinomas and pathological negative pelvic lymph nodes: a retrospective follow-up. J Med Virol 80: 694-701, 2008.
57. Mammas IN, Zafiropoulos A, Koumantakis E, Sifakis S and Spandidos DA: Transcriptional activation of H- and N-ras oncogenes in human cervical cancer. Gynecol Oncol 92: 941-948, 2004.
58. Karlson J, Borg-Karlson AK, Unelius R, et al: Inhibition of tumor cell growth by monoterpenes in vitro: evidence of a Ras-independent mechanism of action. Anticancer Drugs 7: 422-429, 1996.
59. Sklar MD: The ras oncogenese increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239: 645-647, 1988.
60. Van Cutsem E, van de Velde H, Karasek P, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22: 1430-1438, 2004.
61. Zhu K, Hamilton AD and Sebti SM: Farnesyltransferase inhibitors as anticancer agents: current status. Curr Opin Investig Drugs 4: 1428-1435, 2003.
62. Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319, 2000.
63. Vos MD, Ellis CA, Bell A, Birrer MJ and Clark GJ: Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 275: 35669-35672, 2000.
64. Cohen Y, Singer G, Lavie O, Dong SM, Beller U and Sidransky D: The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res 9: 2981-2984, 2003.
65. Kuzmin I, Liu L, Dammann R, et al: Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res 63: 1888-1893, 2003.
66. Kang S, Kim HS, Seo SS, Park SY, Sidransky D and Dong SM: Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol Oncol 105: 662-666, 2007.
67. De Castro Junior G, Puglisi F, de Azambuja E, El Saghir NS and Awada A: Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the 'do ut des' paradigm). Crit Rev Oncol Hematol 59: 40-50, 2006.
68. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
69. Brat DJ, Kaur B and VanMeir EG. Genetic modulation of hypoxia induced gene Expression and angiogenesis: relevance to brain tumors. Front Biosci 8: 100-116, 2003.
70. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007.
71. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
72. Imamura T, Kikuchi H, Herraiz MT, et al: HIF-1alpha and HIF-2alpha have divergent roles in colon cancer. Int J Cancer 124: 763-771, 2009.
73. Walboomers JMM, Jacobs MV, Manos MM, Bosh FX, Kummer JA, Shah KV, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999.
74. Chen W, Li F, Mead L, White H, Walker J, Ingram DA, et al: Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. Virology 367: 168-174, 2007.
75. Gaffney DK, Haslam D, Tsodikov A, Hammond E, Seaman J, Holden J, et al: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radio-therapy. Int J Radiat Oncol Biol Phys 56: 922-928, 2003.
76. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE and Roman LD: Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 27: 1069-1074, 2009.
77. López-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J and Kerbel RS: Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19: 4611-4620, 2000.
78. Coussens LM, Hanahan D and Arbeit JM: Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol 149: 1899-1917, 1996.
79. Smith-McCune KK and Weidner N: Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 54: 800-804, 1994.
80. Bequet-Romero M and López-Ocejo O: Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem Biophys Res Commun 277: 55-61, 2000.
81. Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, et al: Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 103: 489-493, 2006.
82. Bachtiary B, Schindl M, Potter R, Dreier B, Knocke TH, Hainfellner JA, et al: Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9: 2234-2240, 2003.
83. Nakamura M, Bodily JM, Beglin M, Kyo S, Inoue M and Laimins LA: Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses. Virology 387: 442-448, 2009.
84. Shinghi AD and Westra WH: Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 116: 2166-2173, 2010.
85. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: 24-35, 2010.